Key Takeaways Regeneron shares surged 31.5% in six months, driven by pipeline progress and strong earnings.Dupixent growth and label expansions boost revenues, while Eylea faces decline and rising biosimilar pressure.Oncology and new drugs like Libtayo and Lynozyfic support diversification beyond core franchises.The going has been strong for Regeneron Pharmaceuticals (REGN) over the past six months. Shares of this biotech giant have surged 31.5% in this time frame, outpacing the industry’s growth of 13.5%. ...

© 2026 Surrozen, Inc. March 2026 Restoring Vision Through the Science of Renewal Legal Disclaimers This presentation contains certain forward-looking statements within the meaning of the federal securities laws. Forward-looking statements generally are accompanied by words such as "will," "plan," "intend," "potential," "expect," "could," or the negative of these words and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-look ...

Summary of XOMA Corporation Conference Call Company Overview - **Company**: XOMA Corporation (NasdaqGM:XOMA) - **Industry**: Biotechnology - **Key Leadership**: CEO Owen Hughes, CFO Jeff Trigilio, Chief Investment Officer Brad Sitko Core Points and Arguments - **Portfolio Strategy**: XOMA aims to increase optionality within its portfolio, focusing on building a robust pipeline to withstand the binary nature of biotech. The company has 15 assets in phase 3 development, with 2 recent failures attributed to a higher-than-expected placebo effect. Despite this, the company's valuation remains stable, indicating confidence in its portfolio's potential [6][7]. - **Asset Growth**: Over the past three years, XOMA has added approximately 80 assets while reducing its share count, demonstrating effective capital management and a strategy to leverage future returns without diluting equity [8]. - **Tremfya Economics**: XOMA has a claim related to the commercialization of Tremfya, which it believes is integral to the drug's development. Although a recent arbitration was unsuccessful, the company sees potential in pursuing Johnson & Johnson for royalties, with a market cap of $450-$500 million and significant potential financial upside if successful [9][12][14]. - **Litigation Outlook**: The company is optimistic about the potential for a settlement or favorable ruling in its ongoing litigation, which could provide additional funding for business development and shareholder returns [19][22][27]. - **Takeda Transaction**: In 2025, XOMA completed a significant transaction with Takeda, exchanging one asset for nine additional assets, enhancing its portfolio and optionality. This deal is part of a broader strategy to diversify risk and increase net present value (NPV) [34][35]. Financial Highlights - **2025 Financial Performance**: XOMA reported over $50 million in top-line revenue, with $33 million from royalty receipts. The company achieved free cash flow positivity and repurchased $16 million of stock, indicating strong financial health [42][43]. - **Future Projections**: The company anticipates continued growth in royalties from approved therapies, with expectations of covering operational expenses and financial obligations through royalties alone by 2027. XOMA has over $620 million in net operating losses (NOLs) and capitalized R&D deductions, allowing it to maintain a low effective tax rate [51][52]. Upcoming Catalysts - **Clinical Trials**: XOMA has several upcoming catalysts, including the phase 2b readout for volixibat and a phase 3 trial for ersodetug, both of which could significantly impact the company's financials and market position [79][85]. - **Vabysmo Royalties**: Currently generating approximately $25 million annually from Vabysmo royalties, with expectations for continued growth. The drug's performance will influence the company's ability to pay off loans and return cash flows to shareholders [89][90]. Additional Insights - **Business Model**: XOMA's strategy focuses on acquiring non-dilutive capital and building a diversified portfolio to mitigate risks associated with biotech investments. The company emphasizes the importance of maintaining a flat share count while pursuing growth opportunities [60][64]. - **Market Positioning**: The company recognizes the challenges in biotech, including the unpredictability of clinical success and market dynamics. XOMA aims to leverage its unique assets and partnerships to create sustainable revenue streams [55][56]. This summary encapsulates the key points discussed during the conference call, highlighting XOMA's strategic direction, financial performance, and future opportunities within the biotechnology sector.

Core Viewpoint - The global pharmaceutical industry is experiencing a new competitive landscape as multinational companies release their 2025 performance reports, with Johnson & Johnson leading in total revenue at $94.193 billion, followed by Eli Lilly with a remarkable growth rate of 44% [1][2]. Group 1: Financial Performance of Major Pharmaceutical Companies - Johnson & Johnson achieved total revenue of $94.193 billion, with its innovative pharmaceuticals and medical technology segments generating $60.401 billion (+6%) and $33.792 billion (+6.1%) respectively [2]. - Eli Lilly reported a total revenue of $65.179 billion, marking a significant growth of 44% [2]. - Roche, Merck, Pfizer, AbbVie, AstraZeneca, and Novartis also showed upward revenue trends, contributing to the steady growth of the global pharmaceutical industry [1][2]. Group 2: Strategic Adjustments and Leadership Changes - Sanofi appointed Belén Garijo as the new CEO, focusing on enhancing the productivity and innovation capabilities of the R&D department [3]. - Merck announced a reorganization of its pharmaceutical business into two segments: oncology and specialty, aiming to maintain its leadership in cancer treatment [3]. - The global pharmaceutical industry is expected to see continued growth differentiation, with only Eli Lilly providing a double-digit revenue growth forecast for 2026 [3]. Group 3: Competition for the "King of Drugs" Title - In 2025, Eli Lilly's Tirzepatide secured the title of "King of Drugs" with a revenue contribution of $36.5 billion, while Merck's Keytruda generated $31.68 billion, marking a 7% increase [6][7]. - Novo Nordisk's Semaglutide followed closely with $36.1 billion in sales, reflecting over 10% growth [7]. - The GLP-1 drug market is becoming increasingly competitive, with both Eli Lilly and Novo Nordisk dominating the landscape [8]. Group 4: Performance in the Chinese Market - AstraZeneca maintained its leading position in the Chinese market with a revenue of $6.654 billion, representing a 4% increase [12]. - Roche and Novartis were among the top three companies in terms of revenue growth in China, with Roche achieving a 10% increase [13]. - Companies are increasingly focusing on local partnerships and innovations to enhance their market presence in China [14]. Group 5: Patent Expiration and New Growth Opportunities - Many multinational pharmaceutical companies are facing significant risks due to impending patent expirations, with some companies exposed to risks as high as 70% [16]. - The industry is witnessing a surge in business development activities, with 142 innovative drug transactions reported in 2025, marking a new high [17]. - Companies are increasingly seeking new growth avenues through mergers, acquisitions, and collaborations to mitigate the impact of patent cliffs [19].

Core Insights - The weight loss market is expanding, and while Eli Lilly and Novo Nordisk are current leaders, other companies like Regeneron and Roche are emerging as potential investment opportunities due to their diversified portfolios and innovative products. Group 1: Regeneron - Regeneron reported strong phase 2 results for its weight-loss candidate, trevogrumab, which minimizes muscle loss in patients taking GLP-1 medicines, averting about half of the lean mass loss associated with semaglutide [3][4] - Regeneron's approach allows trevogrumab to be prescribed alongside existing treatments like Wegovy, avoiding direct competition with market leaders [4] - The company is also developing a GLP-1 medicine, olatorepatide, with phase 3 studies expected to start this year, indicating potential for significant clinical progress [6] - Regeneron's primary growth driver is Dupixent, an eczema treatment, and it has a vast pipeline that could lead to additional product launches in the coming years [7] Group 2: Roche - Roche reported strong phase 2 results for its anti-obesity candidate, CT-388, showing a placebo-adjusted weight loss of 22.5% over 48 weeks at the highest dose, positioning it competitively against leading weight-loss drugs [8] - The company is preparing for phase 3 studies to confirm these results, establishing itself as a notable player in the next-generation obesity medicine race [8] - Roche has a diversified healthcare business with several growth drivers in pharmaceuticals, including Ocrevus for multiple sclerosis and Vabysmo, alongside a deep pipeline of 66 new molecular entities [10]

Summary of the Conference Call Company Overview - **Company**: Surrozen - **Industry**: Biotechnology, specifically focusing on retinal vascular diseases - **Key Products**: SZN-8141 and SZN-413, targeting Wnt biology and VEGF inhibition Core Points and Arguments Company Strengths - Surrozen combines expertise in Wnt biology with multivalent antibody technology, focusing on retinal vascular diseases [2][3] - Unique approach of combining Wnt, VEGF, and IL-6 inhibition in a single molecule, SZN-8141, which is currently the only known product to do so [2][3] Challenges - The company is in the execution phase, with an IND filing planned for 2026 [3] - Current therapies primarily slow disease progression rather than improve visual outcomes, highlighting the need for innovative solutions [3] Opportunities - Potential to improve visual and anatomic outcomes in diabetic macular edema and wet AMD [3] - The ability to stimulate normal vessel growth in the retina, which is a unique aspect of Wnt biology [4] Product Details - **SZN-8141**: An IgG-based multispecific molecule that activates Wnt signaling by binding to Fzd4 and LRP5 receptors, while also acting as a VEGF trap [9][10] - Preclinical data indicates that SZN-8141 shows synergistic benefits compared to existing therapies like EYLEA [12] Clinical Development - The first human trial design is still being finalized, with an emphasis on determining dosing and patient endpoints [18][19] - The company plans to conduct a phase 1b/2a study with ascending doses to evaluate visual acuity and retinal drying [19] Competitive Landscape - Merck's program, which is similar, has two phase 3 trials ongoing, with top-line data expected in September 2023 [26] - Surrozen aims to demonstrate that combining multiple mechanisms in one antibody will yield better outcomes than single-target therapies [27] Financial Aspects - Surrozen has a cash balance of approximately $80 million, with additional funding expected upon IND clearance [102] - The company is currently self-funding its clinical studies for SZN-8141 and SZN-8143, indicating a strong financial position for development [96] Safety and Risks - No theoretical risks associated with combining VEGF and Wnt inhibition have been identified, although immunogenicity risks are always a concern with large molecules [42][87] - Recent studies have shown some retinal vascular occlusions, but these are not deemed above the expected background rate [88] Future Directions - Surrozen plans to advance both SZN-8141 and SZN-8143, with SZN-8143 targeting more inflammatory-driven diseases [63][64] - The company is optimistic about the potential for IL-6 inhibition to provide additive benefits in retinal diseases [68][70] Additional Important Information - The market for retinal diseases is becoming increasingly attractive, with growing strategic interest from larger pharmaceutical companies [100][101] - Surrozen's strategy includes leveraging the small number of retinal specialists in the U.S. for commercialization, making it a tractable market for a small biotech firm [96][97]

Core Insights - Roche's late-stage study FENhance 1 for fenebrutinib in relapsing multiple sclerosis (RMS) met its primary endpoint, showing significant efficacy [1][8] - Fenebrutinib demonstrated a 51% reduction in RMS relapses compared to teriflunomide in FENhance 1, with FENhance 2 showing a 59% reduction [3][8] - The comprehensive data from the phase III studies will be submitted to regulatory authorities, with the potential for fenebrutinib to become a leading oral therapy for both RMS and primary progressive multiple sclerosis (PPMS) [5][8] Study Details - The phase III program includes two trials in RMS (FENhance 1 and 2) and one trial in PPMS (FENtrepid), evaluating fenebrutinib against teriflunomide and Ocrevus respectively [2] - FENhance 1 and FENhance 2 involved 1,497 adult patients and were designed as multicenter, randomized, double-blind studies [3] Safety and Efficacy - Safety findings were comparable to teriflunomide, with similar liver enzyme elevations and one case of Hy's Law in each treatment arm, both resolving after treatment discontinuation [5] - Secondary endpoints showed statistically significant reductions in brain lesions, indicating strong benefits across both relapsing and progressive disease processes [4] Portfolio Impact - Successful development of fenebrutinib will enhance Roche's neuroscience portfolio, which includes Ocrevus, a key growth driver for the company [6] - Roche is actively developing over a dozen therapies for various neurological conditions, including multiple sclerosis and Alzheimer's disease [6] Competitive Landscape - Roche's Ocrevus and Vabysmo are performing strongly, helping to offset revenues from legacy drugs [7] - Positive data from fenebrutinib and other candidates like giredestrant may increase the likelihood of regulatory approval, serving as a catalyst for Roche's stock [9]

Summary of Ocular Therapeutix FY Conference Call Company Overview - **Company**: Ocular Therapeutix (NasdaqGM: OCUL) - **Event**: FY Conference on March 02, 2026 - **Key Speaker**: Pravin U. Dugel, CEO Core Industry Insights - **Industry**: Biopharmaceuticals, specifically focusing on retinal diseases and treatments - **Key Product**: AXPAXLI, a drug aimed at treating retinal diseases, with a focus on its superiority over existing anti-VEGF treatments Key Points and Arguments 1. **Positive Study Outcome**: The SOL-1 study achieved a positive outcome, marking the first superiority study in the retina field to meet its primary endpoint, with a p-value of 0.0006, indicating statistical significance [2][8][25] 2. **Study Design**: The study was conducted under a Special Protocol Assessment (SPA) from the FDA, making it unique and unprecedented in its design [2][25] 3. **Data Transparency**: Ocular Therapeutix provided extensive data (129 slides) to address questions and concerns raised post-study announcement, emphasizing the consistency of the data across various analyses [3][4][5] 4. **Visual Acuity Loss**: The study highlighted the time it takes for significant vision loss to occur, with a focus on the clinical significance of the OCT results, which showed a high degree of disease control [8][20] 5. **Rescue Patients Analysis**: The analysis of patients who required rescue injections indicated that the AXPAXLI drug performed well even in a biased patient population, with results still being favorable compared to EYLEA [17][19] 6. **Superiority Label Importance**: The CEO emphasized the potential for AXPAXLI to receive a superiority label, which would protect its pricing and market position against competitors, particularly in a landscape filled with non-inferiority studies [25][27] 7. **Community vs. Clinical Trial Performance**: The CEO expressed confidence that AXPAXLI would perform better in real-world settings than in clinical trials, as the trial population was designed to lose vision [32][33] 8. **Regulatory Pathway**: Ocular Therapeutix is optimistic about submitting for approval based on a single trial, citing the robustness of their data and the SPA agreement with the FDA [64][65] 9. **Broad Label Expectations**: The company anticipates a broad label for diabetic retinopathy and diabetic macular edema, which would encompass all patients with these conditions [66][67] Additional Important Insights - **Safety Profile**: The CEO addressed concerns regarding floaters and cataracts, clarifying that reported floaters were drug particles observed by physicians and did not affect vision [60][63] - **Market Positioning**: The company aims to differentiate AXPAXLI from competitors like EYLEA and Vabysmo, highlighting its longer duration of effect and potential for better patient outcomes [48][49] - **Physician Perspectives**: There is a disconnect between analysts' focus on labeling and physicians' practical use of the drug, with physicians prioritizing treatment efficacy over label specifics [22][23][27] This summary encapsulates the key discussions and insights from the Ocular Therapeutix conference call, focusing on the company's recent study outcomes, product positioning, and future regulatory strategies.

Surrozen (NasdaqCM:SRZN) Conference Call Summary Company Overview - Surrozen is a biotech company founded in 2016, focusing on Wnt biology and antibody engineering, particularly in retinal diseases [3][4] Core Points and Arguments Wnt Pathway and Retinal Diseases - The Wnt pathway is critical for the development and maintenance of various tissues, including the eye [3] - Surrozen is targeting the Fzd4 receptor, which is essential for normal retinal vessel function [4] - Diseases associated with the loss of function of the Wnt pathway include rare conditions like Norrie Disease and FEVR, but the focus is on more prevalent retinal vascular diseases such as diabetic macular edema (DME) and wet age-related macular degeneration (AMD) [6][7] Competitive Landscape - Surrozen's lead molecule is positioned against competitors like Merck, which has a similar pharmacological approach and is currently in Phase III trials [6][7][29] - The current market is dominated by Roche's Vabysmo and Eylea, which are anti-VEGF therapies [29] Mechanism of Action - Surrozen's approach involves activating the Wnt pathway to restore normal vessel architecture and function, contrasting with existing therapies that inhibit pathological factors like VEGF [17][20] - Activation of the Wnt pathway is shown to upregulate tight junction proteins, which help seal leakage in retinal endothelial cells, particularly relevant in DME [19][20] Clinical Development - Surrozen has three programs: two internal molecules (8141 and 8143) and one partnered with Boehringer Ingelheim (SZN-413) [27][82] - The IND for molecule 8141 is expected to clear in 2026, with ongoing IND-enabling work [41][61] - Molecule 8141 is a bispecific tetravalent antibody targeting Wnt and VEGF, while 8143 adds IL-6 inhibition, making it trifunctional [71][72] Upcoming Milestones - The first Phase III trial data for Merck's molecule is expected in September 2026, which could validate the Wnt pathway's role in treating retinal diseases [75] - Surrozen anticipates updates on the IND timelines and further details on clinical trial designs soon [70][88] Intellectual Property and Financial Health - Surrozen has a robust patent estate with approximately 38 applications, focusing on multivalent Frizzled and LRP5/6 binding antibodies [89] - The company completed a PIPE in March 2025, raising $175 million, with $80 million in cash reported at the end of Q3 2025 [90] Other Important Information - The partnership with Boehringer Ingelheim has yielded $22.5 million, with hopes for clinical advancement of SZN-413 [82][85] - Roche's acquisition of Frizzled and LRP binders from University of Toronto is noted, but no updates on their progress have been provided [87] This summary encapsulates the key points discussed during the conference call, highlighting Surrozen's strategic focus, competitive positioning, and future milestones in the context of retinal disease treatment.

Core Insights - Regeneron Pharmaceuticals (REGN) reported a solid performance for Q4 2025 and full-year 2025, with overall revenues increasing despite a significant decline in sales of its flagship product, Eylea [1] Eylea Performance - Eylea sales in the U.S. fell by 42% to $2.7 billion in 2025, driven by competitive pressures, market share loss to compounded bevacizumab, and patient transitions to Eylea HD [2] - Eylea remains Regeneron's largest revenue contributor, but declining sales are impacting overall revenues [3] - Eylea HD, a higher-dose formulation, saw sales increase by 36% to $1.6 billion in the U.S. in 2025, as Regeneron aims to defend its market share [5][10] Competitive Landscape - Roche's Vabysmo has intensified competition, achieving sales growth of 12% to CHF 4.1 billion in 2025 [4] - Regeneron introduced Eylea HD to improve durability and extend dosing intervals in response to competitive pressures [4] Future Projections - Eylea sales are expected to decline further in 2026, particularly in the second half of the year as multiple biosimilars enter the U.S. market [5][10] - Eylea HD is gaining traction due to steady label expansions, with recent FDA approvals enhancing its market position [6][7] Other Revenue Streams - Regeneron's revenue is bolstered by its share of profits from global Dupixent sales, which continue to grow due to strong demand across various indications [8] - Libtayo, Regeneron's PD-1 inhibitor, generated $1.4 billion in sales in 2025, reflecting a 19% year-over-year increase [11] Oncology Developments - The oncology portfolio received a boost with the FDA's accelerated approval of linvoseltamab-gcpt for relapsed or refractory multiple myeloma [12] - The European Commission approved Ordspono for relapsed or refractory follicular lymphoma or diffuse large B-cell lymphoma, further strengthening Regeneron's oncology franchise [13] Pipeline and Future Approvals - Regeneron has a robust pipeline, with additional drug approvals expected to support revenue growth [13] - The company submitted a biologics license application for DB-OTO, a gene therapy for profound genetic hearing loss, with a decision expected in H1 2026 [14] - Regeneron is also pursuing approval for garetosmab for fibrodysplasia ossificans progressiva and expanding its obesity-focused pipeline [15]